Sanofi has appointed Bill Sibold as executive vice president of Sanofi Genzyme, the specialty care global business unit of Sanofi that focuses on rare diseases, multiple sclerosis, oncology, and immunology, effective July 1, 2017. Mr. Sibold succeeds David Meeker, MD, who will leave the company at the end of June 2017. In this role, Mr. Sibold will be a member of Sanofi’s executive committee.
Mr. Sibold currently serves as head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, a position he has held since January 2016 and where he has led preparation for the global launches of dupilumab and sarilumab, monoclonal antibodies (mAbs) that Sanofi Genzyme is developing in collaboration with Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company. Mr. Sibold joined Sanofi in late 2011 as head of the multiple sclerosis franchise where he oversaw the launches of Aubagio (teriflunomide) and Lemtrada (alemtuzumab). As head of Sanofi Genzyme, Mr. Sibold will now lead the company’s efforts in rare diseases while continuing to grow in multiple sclerosis, oncology, and immunology.
Mr. Sibold has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly and Company. He held a number of leadership positions within Biogen, including driving their US commercial operations in neurology, oncology, and rheumatology and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Mr. Sibold also served as the chief commercial officer of Avanir Pharmaceuticals.